Comerica Bank’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Comerica Bank’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-500	Closed	-$7.38K	–	3856
2024 Q1	$7.38K	Hold	500	–	–	﹤0.01%	3251
2023 Q4	$6.71K	Hold	500	–	–	﹤0.01%	3247
2023 Q3	$6.17K	Buy	+500	New	+$6.05K	﹤0.01%	3312

Other funds holding MACK

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Comerica Bank's MACK Position: Q2 2024 in Review

Comerica Bank sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 500 shares — an estimated $7.38K sold.

Comerica Bank first reported a position in MACK in Q3 2023 and held it in 3 quarters. The position peaked at $7.38K in Q1 2024. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

Comerica Bank reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
Comerica Bank sold 500 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $7.38K.
Comerica Bank first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2023 and held it in 3 quarters.
Comerica Bank's Merrimack Pharmaceuticals, Inc. position peaked at $7.38K in Q1 2024.
12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on Comerica Bank's 13F filing for Q2 2024, filed 15 Aug 2024.